• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Nintedanib may be effective in slowing the progression of interstitial lung disease

byThomas SuandDeepti Shroff Karhade
July 18, 2020
in Chronic Disease, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In this phase 3 trial, patients with fibrosing lung disease who received nintedanib experienced a much slower rate of decline in forced vital capacity compared to those who received placebo.

2. Patients in the nintedanib group were more likely to experience gastrointestinal discomfort and elevations in liver enzymes versus placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The tyrosine kinase inhibitor nintedanib has been suggested to delay the progression of a number of lethal lung disorders including idiopathic pulmonary fibrosis and systemic sclerosis-associated interstitial lung disease. Given the many clinical and pathophysiological commonalities between such conditions, it has been hypothesized that a broad range of other progressive fibrosing disorders may be similarly receptive to treatment with this drug. This study found that, compared to the placebo group, patients with fibrosing interstitial lung disease who received nintedanib experienced a significantly smaller decrease in forced vital capacity and a more favorable change in score on the King’s Brief Interstitial Lung Disease questionnaire after 52 weeks. The rates of adverse events of any severity were similar between groups, but those receiving nintedanib were more likely to experience an adverse event leading to permanent dose reduction or discontinuation of treatment. Additionally, over two thirds of patients in the nintedanib group reported having diarrhea compared to only one fourth of patients in the placebo group. Strengths of this study included patient diversity, stratification according to fibrotic pattern, and use of a Hochberg procedure in statistical analysis. However, due to the breadth of the inclusion criteria, it remained difficult to determine the relative efficacy of nintedanib in the treatment of specific conditions since results may not have applied equally to all patient subsets.

Click here to read the study in NEJM

Relevant Reading: The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis

In-Depth [randomized controlled trial]: This randomized, double-blind, placebo-controlled, parallel-group trial was conducted at 153 sites in 15 countries and recruited 663 adults with any fibrosing interstitial lung disease affecting more than 10% of lung volume as shown on high-resolution computed tomography. Patients were also required to demonstrate downward trends in forced vital capacity (FVC), respiratory symptoms, and extent of fibrosis. After stratification by imaging pattern (usual interstitial pneumonia (UIP) like or other), patients were randomized to receive either oral nintedanib at a dose of 150 mg twice daily or placebo. The overall adjusted rate of decline in FVC was -80.8 mL/year in the nintedanib group versus -187.8 mL/year in the placebo group (between-group difference, 107.0 ml; 95% confidence interval [CI], 65.4 to 148.5; P<0.001). This difference was even greater in patients with a UIP-like pattern, with those receiving nintedanib experiencing a rate of decline of -82.9 mL/year versus −211.1 mL/year in those receiving placebo (between-group difference, 128.2 ml; 95% CI, 70.8 to 185.6; P<0.001). In the overall population, the adjusted change in the total score on the King’s Brief Interstitial Lung Disease questionnaire after 52 weeks was 0.55 points in the nintedanib group and −0.79 points in the placebo group (between-group difference, 1.34 points; 95% CI, −0.31 to 2.98). Finally, while the percentages of patients with adverse events remained similar between groups, those in the nintedanib group were more likely to experience an event leading to either dose reduction (33.1% vs. 4.2%) or discontinuation of treatment (19.6% vs. 10.3%).

RELATED REPORTS

Exposure to particulate matter 2.5 μm or less associated with adverse outcomes among patients with fibrotic interstitial lung disease

Phosphodiesterase 4 inhibitor BI 1015550 preserves lung function in pulmonary fibrosis patients

INPULSIS: Nintedanib for Idiopathic Pulmonary Fibrosis [Classics Series]

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: fibrosing interstitial lung diseaseforced vital capacity (FVC)nintedanibtyrosine kinase inhibitor
Previous Post

The 3 Wishes Project: a valuable program to improve end-of-life care

Next Post

#VisualAbstract: Complete Revascularization with Multivessel PCI for Myocardial Infarction

RelatedReports

Lessons from real-world implementation of lung cancer screening
Chronic Disease

Exposure to particulate matter 2.5 μm or less associated with adverse outcomes among patients with fibrotic interstitial lung disease

October 27, 2022
Interstitial lung abnormalities linked to greater risk of all-cause mortality
Chronic Disease

Phosphodiesterase 4 inhibitor BI 1015550 preserves lung function in pulmonary fibrosis patients

June 18, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Radiology Classics

INPULSIS: Nintedanib for Idiopathic Pulmonary Fibrosis [Classics Series]

June 16, 2022
#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia
StudyGraphics

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia

June 12, 2022
Next Post
#VisualAbstract: Complete Revascularization with Multivessel PCI for Myocardial Infarction

#VisualAbstract: Complete Revascularization with Multivessel PCI for Myocardial Infarction

Infant room-sharing associated with less nighttime sleep and unsafe sleep practices

Association of Widespread Adoption of the 39-Week Rule With Overall Mortality Due to Stillbirth and Infant Death

Quick Take: Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial

Odanacatib for the treatment of postmenopausal osteoporosis

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia
  • Plant-based diets may be associated with lower risk of aggressive prostate cancer
  • #VisualAbstract: Adagrasib provides antitumour activity against KRAS G12C mutant metastatic colorectal cancer both as monotherapy and in combination with cetuximab
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options